Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insuli...
Main Authors: | Jacob E. Pruett, Damian G. Romero, Licy L. Yanes Cardozo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.951099/full |
Similar Items
-
Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19
by: Samar Rezq, et al.
Published: (2021-09-01) -
SARS-CoV-2 Viral Entry Proteins in Hyperandrogenemic Female Mice: Implications for Women with PCOS and COVID-19
by: Alexandra M. Huffman, et al.
Published: (2021-04-01) -
Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome
by: Jacob E. Pruett, et al.
Published: (2021-03-01) -
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: A Review
by: Rachel Porth, et al.
Published: (2024-02-01) -
Psychiatric Disorders in Infertile Women with Polycystic Ovary: Prevalence and Associated Factors
by: Mohammed Abo-Elabbas, et al.
Published: (2022-09-01)